GlassScriptPhysician profile
Thomas P Bradley
NPI 1902979644
$8,190.13
in general payments reported to CMS, 2019-2025
52 companies · $911 in 2025
The $911 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,632 · 2020: $1,216 · 2021: $1,006 · 2022: $1,097 · 2023: $1,035 · 2024: $1,293 · 2025: $911.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,214 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,213.91 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,162.85 | 2019-2025 | Darzalex, Erleada, Talvey |
| E.R. Squibb & Sons, L.L.C. | $989.88 | 2019-2025 | Opdivo, Camzyos |
| Pfizer INC. | $538.27 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $469.74 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $353.78 | 2019-2025 | Lynparza, Enhertu, Tagrisso |
| Eisai INC. | $346.06 | 2019-2025 | |
| Astellas Pharma US INC | $289.32 | 2019-2025 | Padcev, Xtandi, Xospata |
| Lilly USA, LLC | $272.56 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Exelixis INC. | $216.39 | 2019-2024 | Cabometyx |
| Merck Sharp & Dohme LLC | $206.36 | 2019-2024 | Lynparza, Keytruda |
| Seagen INC. | $198.43 | 2019-2023 | Adcetris |
| Daiichi Sankyo INC. | $171.08 | 2019-2025 | Enhertu, Datroway |
| Genentech USA, INC. | $160.67 | 2019-2022 | |
| Glaxosmithkline, LLC. | $160.26 | 2020-2023 | Zejula |
| Celgene Corporation | $144.92 | 2022-2024 | Reblozyl |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $142.23 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $141.58 | 2019-2024 | Xarelto |
| Array Biopharma INC | $137.69 | 2021-2025 | Mektovi, Braftovi, Xalkori |
| Rigel Pharmaceuticals, INC. | $137.42 | 2019-2025 | Rezlidhia, Tavalisse, Gavreto |
| Secura Bio, INC. | $134.05 | 2023-2025 | Copiktra |
| Abbvie INC. | $132.02 | 2019-2024 | |
| Genzyme Corporation | $129.49 | 2019-2025 | |
| Aveo Pharmaceuticals, INC. | $100.37 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $93.51 | 2019-2023 | Ninlaro |
| Foundation Medicine, INC. | $89.81 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $87.14 | 2019-2021 | |
| Pharmaessentia USA Corporation | $84.33 | 2024-2025 | Besremi |
| Stemline Therapeutics INC. | $76.59 | 2020-2024 | Orserdu |
| Incyte Corporation | $74.07 | 2020-2025 | Monjuvi |
| Taiho Oncology, INC. | $73.81 | 2019-2025 | |
| Blueprint Medicines Corporation | $70.88 | 2021-2024 | Ayvakit |
| Bayer Healthcare Pharmaceuticals INC. | $70.46 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $70.06 | 2020-2025 | Libtayo |
| Kite Pharma, INC. | $66.88 | 2021-2025 | Yescarta |
| Adc Therapeutics America, INC. | $54.92 | 2023-2024 | |
| Coherus Oncology, INC. | $53.45 | 2024-2025 | Loqtorzi |
| Sobi, INC | $52.18 | 2022-2024 | |
| Servier Pharmaceuticals LLC | $45.79 | 2022-2025 | |
| Karyopharm Therapeutics INC. | $38.38 | 2021 | |
| Genentech, INC. | $38.00 | 2019 | |
| Gilead Sciences, INC. | $37.74 | 2019-2021 | |
| Emd Serono, INC. | $30.98 | 2023 | Bavencio |
| Geron Corporation | $30.37 | 2025 | Rytelo |
| Beigene USA, INC. | $30.05 | 2024 | Tevimbra |
| Cti Biopharma Corp. | $27.49 | 2023 | Vonjo |
| Pharmacyclics LLC, An Abbvie Company | $25.65 | 2020 | |
| Epizyme, INC. | $23.67 | 2021 | |
| Novocure INC. | $23.47 | 2024 | Optune |
| Agios Pharmaceuticals, INC. | $23.28 | 2019 | |
| Tactile Systems Technology INC | $23.21 | 2025 | Nimbl, Flexitouch Plus |
| Collegium Pharmaceutical, INC. | $20.68 | 2019 | |
| Dova Pharmaceuticals | $17.86 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Bradley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.